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Background: The role of lung function monitoring in subjects identified as having asymptom-
atic alpha-1 antitrypsin deficiency (AATD) is uncertain. We investigated for the first time the
age these tests start to deviate from results expected in a healthy population with particular
reference to the group with the best prognosis (non-smokers), and the order in which this
occurs.
Methods: Spirometry, gas transfer, health status, and CT densitometry for upper and lower
zones were examined in relation to age, gender, ascertainment method and smoking in 591
PiZ AATD subjects using two methods. Firstly, determining the earliest age group at which
>50% of subjects consistently had actual test results worse than the healthy population mean
by data observation, and secondly predicting the age when this occurred using a logistic
regression model.
Results: Both methods produced similar results. For non-index subjects, gas transfer and
health status deviated from normal before the age of 16, followed by upper zone densitometry
and FEV1:FVC ratio (age 29), and finally lower zone densitometry and FEV1 (age 37). This order
was similar in non-index never smokers, but occurred later (from the age of 29e63).pital Birmingham NHS Foundation Trust, Birmingham, UK.
ospital Birmingham NHS Foundation Trust, UK. Tel.: þ44 0121 371 2000; fax: þ44 0121 371 3887.
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388 J. Holme et al.Conclusions: Gas transfer, health status and CT densitometry deviate from normal from the
mid-teens (up to 30 years prior to conventional spirometry) in AATD.
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Alpha-1 antitrypsin deficiency (AATD) is a genetic condition
predisposing to chronic obstructive pulmonary disease
(COPD).1 Alpha-1 antitrypsin (AAT) is a glycoprotein2
produced mainly in hepatocytes,3 and released in the
bloodstream to the lung where it is the principal inhibitor of
serine proteases, such as neutrophil elastase.4 In PiZ AATD,
a point mutation causes an abnormal AAT protein to be
produced, which is prone to polymerisation5 and subse-
quent blockage of the terminal secretory pathway in
hepatocytes.6 This leads to retention of most of the protein
in the liver and only a small percentage reaches the
circulation and lung.
Neutrophil elastase plays an important role in host
defence by catalysing the breakdown of micro-organisms
that can lead to infection in the lung, and in the clearance
of necrotic lung tissue.7 However, if left unopposed in the
lung (as in PiZ AATD), it can also cause damage similar to
that seen in COPD, including alveolar destruction leading to
emphysema,8 loss of ciliated epithelium,9 squamous cell
metaplasia,10 reduced ciliary beat frequency11 and mucous
gland hyperplasia.12
Furthermore, the small amount of PiZ AAT that does
reach the circulation and subsequently the lung is approx-
imately five times less potent as an inhibitor of neutrophil
elastase compared with the normal PiM type of AAT
protein13e16 decreasing its protective role even further.
Despite this, the development of lung disease is not
inevitable, but the risk of developing disease,17 its’ progres-
sion18 and mortality19 are greatly increased by smoking.
Early detection and monitoring is important to identify
subjects who are developing lung disease, particularly to
emphasise smoking cessation and introduce treatment,
especially in light of recent findings from a randomised
controlled trial of augmentation therapy, which showed
some benefit.20 At present most patients are only identified
after seeing several physicians over many years by which
time lung damage is well established.21
The World Health Organisation (WHO) recommended
that all patients with adult onset asthma or COPD should be
tested.22 However, this also delays diagnosis until disease
and symptomatology are established. The alternative is
neonatal screening although this raises some ethical issues.
Nevertheless such an approach was initiated in Sweden in
1972 and 127 PiZ subjects were identified from 200,000
infants. Subjects responded positively to advice about the
hazards of smoking,23 with little psychological impact.
These subjects are undergoing regular monitoring of FEV1
and to-date no group change has been identified in the
subjects who are now in their 30s, although 42% report
breathlessness.24
The Swedish data suggests spirometry may be insensitive
to early change and we have identified subjects with
established emphysema and reduced gas transfer butnormal spirometry,25 suggesting that other tests may be
more informative.
The UK database of AATD subjects (ADAPT) includes
smokers, non-smokers, index (those identified to have
alpha-1 antitrypsin deficiency following investigation of
relevant symptoms) and non-index (those identified only as
a result of family or population screening) subjects who
have undergone extensive assessment including spirometry,
gas transfer, high resolution computed tomography (HRCT)
scanning and health status. We related these parameters to
age to determine when they deviated from normal values in
order to provide a more informed approach to monitoring
for early lung disease especially for those with the best
disease prognosis (non smoking non-index cases).
Methods
The first 591 PiZ ADAPT subjects in the UK National data-
base were included, and data from their baseline visit
analysed. FEV1, the ratio of FEV1 to forced vital capacity
(FEV1:FVC) and carbon monoxide transfer factor corrected
for alveolar volume (KCO) were measured and expressed as
a percentage of predicted as previously described.25
An HRCT had been performed for 563 subjects, and
density mask analysis was available for 368, to determine
the proportion of computed tomography (CT) voxels with
a density of less than 910 HU (Houndsfield Units) in the
upper and lower zone, as described previously.25 The
presence or absence of visible emphysema on CT was
determined using standard radiological criteria. Subjects
completed a St Georges Respiratory Questionnaire (SGRQ)
and demographic data, including smoking history and the
reason for initial diagnosis of AATD were recorded.
The proportions of subjects with abnormal results was
taken as those with an FEV1, FEV1:FVC and KCO of <80%
predicted. There are no defined reference ranges for SGRQ
scores, upper zone voxel index (UZVI) or lower zone voxel
index (LZVI), so we calculated the proportion of subjects
with a score greater than 1.96 standard errors above the
mean data derived from a normal population,26,27 based on
a theoretical reference range encompassing values ob-
tained in 95% of healthy subjects. (Table 3 in the Online
Supplement).
The age at which test parameters start to decline was
determined by 2 methods. Firstly, the cohort was split into
5-year age strata, and the proportion of subjects in each
stratum who had values worse than the healthy population
mean was determined for each measure. The earliest age
group in which this proportion was consistently >50% was
determined.
Secondly, a mathematical model was constructed
including all subjects, using forward logistic regression (SPSS
12.0.1 for Windows, SPSS, Chicago, IL), with FEV1 <100%
predicted as the dichotomous dependant variable, and age,
gender, smoking status and method of ascertainment as co-
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determine the probability of the FEV1 being <100% pre-
dicted, expressed in terms of the covariates stated above.
Coefficients for these covariates were inserted into the
equation to represent the various methods of ascertainment
and smoking statuses and genders. By definition, in a healthy
population, it is expected that half of subjects will have an
FEV1 <100% predicted. We therefore inserted different ages
into the equation to determined the earliest age atwhich the
probability of the FEV1 being <100% predicted was consis-
tently greater than 0.5 (i.e. started to deviate from normal).
Similar models were constructed for FEV1:FVC, KCO,
SGRQ total score, UZVI and LZVI being less than or greater
than the relevant mean for a healthy population as the
dichotomous dependant variables. The mean values used
for the healthy population were 100% predicted for
FEV1:FVC and KCO, and previously published normal values
related to age for the SGRQ.26 No normal values for density
mask analysis at a threshold of 910 HU have been pub-
lished. Therefore, previously published values determined
using a GE Prospeed CT scanner with a density mask analysis
threshold of 912 HU, in subjects who had never smoked
and had no evidence of lung disease on pulmonary physi-
ology and HRCT were used.27
Data were compared between index & non-index
subjects (identified by family screening) and subjects who
had smoked or not using SPSS 12.0.1 for Windows (SPSS,
Chicago, IL). The c2 and Fishers exact tests were used to
compare categorical data, the one-way ANOVA test was
used if continuous data was parametric and the Krus-
kaleWallis test was used for non-parametric data.
Subjects gave written informed consent, and the study
was approved by South Birmingham Research and Ethics
Committee.
Results
Demographic data is shown in Table 1 and the proportion
of subjects with abnormal physiological, radiological
and health status parameters (see Methods) are shown in
Table 2 for index and non-index subjects depending on the
smoking status.Table 1 Demographic, physiological, radiological and health sta
median (IQR) if non-parametric unless otherwise stated.
Non-index never
smoked (n Z 54)
Non-index ex
smokers (n Z
Age 44.8 (13.8) 46.9 (11.4)
Male gender n (%) 18 (33.3%) 49 (51.6%)a
Pack years smoked N/A 12.0 (5.0e21
FEV1% predicted 102.9 (26.7) 76.3 (29.3)
a
FEV1:FVC% predicted 95.0 (20.9) 71.9 (23.2)
a
KCO% predicted 91.0 (20.9) 77.4 (21.5)a
SGRQ total score 22.4 (20.2) 37.5 (24.3)a
Upper zone voxel index (%) 16.1 (13.9) (n Z 35) 20.7 (15.4) (n
Lower zone voxel index (%) 19.5 (16.6) (n Z 35) 31.7 (19.8)a (
a p < 0.05 compared with non-index never smoked.
b p < 0.05 compared with non-index ex/current smokers.
c p < 0.05 compared with index never smoked.Age at which test parameters start to deviate from
normal
5-year age strata method
The numbers of subjects in each 5 year age strata are
shown in Table 4 (Online Supplement). All parameters had
deviated from the mean normal value between the ages of
20 and 30 (Fig. 1). However, index cases accounted for 75%
of subjects and (by definition) were likely to have had
abnormal test results on presentation. The analysis of non-
index cases alone was different, with the FEV1 deviating
from normal in the age range 40e45 whereas other
parameters deviated in the 20e25 and 25e30 age cohorts
(Fig. 2).
Logistic regression method
Gender was not a determinant of any variable so was not
included in any predictive equations. The equations
generated for each variable are shown in Table 5 (Online
Supplement).
Most index cases had a least one physiological (99.5%),
radiological (98.2%) or health status (99.3%) parameter
worse than the healthy population mean at their first visit,
which is reflected in the ages at which deviations from
normal were predicted to occur. These predicted ages were
understandably less than the age of the youngest patient at
their baseline visit, because most of the data had to be
derived by extrapolation. Therefore, we were unable to use
this model to determine with any confidence the ages at
which test parameters started to deviate from normal in
the index subjects as by definition they had already pre-
sented with symptoms.
However, the results obtained for non-index cases do not
involve data extrapolation but utilise primary information.
The ages at which each variable is predicted to deviate
from normal are shown in Fig. 2 for all non-index cases. The
SGRQ and KCO are predicted to deviate from normal before
the age of 16. Following this, UZVI and FEV1:FVC were
predicted to deviate from normal at age 29, then LZVI and
FEV1 (age 37).
To explore the model further in non-index subjects we






smokers (n Z 352)
60.5 (11.4)a,b 49.7 (9.1)a,c
53 (58.9%)a 227 (64.5%)a,b
.5) N/A 21.0 (12.8e28.0)
65.2 (28.5)a,b 43.2 (19.6)a,b,c
63.3 (23.7)a,b 45.4 (16.9)a,b,c
73.6 (24.2)a 62.3 (19.8)a,b,c
42.2 (17.7)a 54.2 (18.0)a,b,c
Z 58) 28.9 (17.1)a,b (n Z 47) 35.9 (16.4)a,b,c (n Z 227)
n Z 58) 40.0 (22.1)a (n Z 47) 51.9 (16.2)a,b,c (n Z 227)
Table 2 Percentage of subjects with abnormal physiological, radiological and health status parameters at baseline.
Non-index never
smoked (n Z 54)
Non-index ex/current
smokers (n Z 95)
Index never
smoked (n Z 90)
Index ex/current
smokers (n Z 352)
FEV1 < 80% predicted 16 52
a 72a,b 95a,b,c
FEV1:FVC < 80% predicted 16 61
a 73a 96a,b,c
KCO < 80% predicted 19 54a 60a 84a,b,c
SGRQ total score > 1.96 SEM
above mean
65 83a 97a,b 100a,b,c
UZVI > 1.96 SEM above mean 69 79 92a 97a,b
LZVI > 1.96 SEM above mean 9 36a 52a 73a,b,c
Emphysema on CT scan 20 (n Z 49) 54a (n Z 86) 64a (n Z 88) 69a,b (n Z 340)
a p < 0.05 compared with non-index never smoked.
b p < 0.05 compared with non-index ex/current smokers.
c p < 0.05 compared with index never smoked.
390 J. Holme et al.status as an additional covariate. The equations generated
are shown in Table 6 (Online Supplement). Smoking status
was related to all variables except UZVI.
For non-index never smokers (Fig. 3a) which represents
the group with the best prognosis, the earliest test pre-
dicted to deviate from normal was the SGRQ and UZVI
(age 29), then KCO (age 32), FEV1:FVC and LZVI (age 50) and
finally FEV1 (age 63).
For non-index ex and current smokers (Fig. 3b), SGRQ
and KCO were again among the earliest results predicted
to deviate from normal (age < 16), followed by FEV1:FVC
(age 17), FEV1 (age 24) then UZVI and LZVI (age 29).
Discussion
Using two methods (one observational and one predictive),
we have demonstrated for the first time that KCO deviates
from normal up to 30 years before spirometry in non-index
subjects with AATD. This is associated with a deterioration
in health status and CT densitometry especially in never-Figure 1 Age at which physiological, radiological and health
status parameters had deviated from normal values for the
whole study population. White columns represent values ob-
tained using the age strata method. The black columns
represent values obtained for males using the logistic regres-
sion method. The grey columns represent values obtained for
females using the logistic regression method.smokers, and may explain why a high proportion of the
Swedish AATD cohort have normal spirometry yet complain
of breathlessness.24
Previous studies suggest that spirometry becomes
abnormal from age 50e65 in never-smokers28,29 and from
25 years in smokers.30 This is consistent with both our
observations and predictions from logistic regression.
Although no similar age predictions have been quoted for
non-index subjects per se, Seersholm and Kok-Jensen30
noted that non-index patients had higher spirometry
values than index subjects, and FEV1% predicted was <70%
in only 11%, again in general agreement with this study.
Although there is no previous data available regarding
the age at which gas transfer, health status and CT
scans become abnormal in AATD, a high proportion of the
Swedish cohort had breathlessness, wheeze and sputum
production from age 16, despite spirometry being normal at
30 years of age,24 suggesting that pathological changes and
clinical symptomatology occur before spirometry becomes
abnormal. This is consistent with our observations showing
deviation of health status, KCO and, in never-smokers, CT
densitometry, several years before spirometry.Figure 2 Age at which physiological, radiological and health
status parameters had deviated from normal values for non-
index subjects only. White columns represent values obtained
using the age strata method. The black columns represent
values obtained for males using the logistic regression method.
The grey columns represent values obtained for females using
the logistic regression method.
Figure 3 a: Age at which physiological, radiological and
health status parameters had deviated from normal values for
non-index subjects who had never smoked. White columns
represent values obtained using the age strata method. The
black columns represent values obtained for males using the
logistic regression method. The grey columns represent values
obtained for females using the logistic regression method. b:
Age at which physiological, radiological and health status
parameters had deviated from normal values for non-index
subjects who had previously or who currently smoke. White
columns represent values obtained using the age strata
method. The black columns represent values obtained for
males using the logistic regression method. The grey columns
represent values obtained for females using the logistic
regression method.
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earliest tests to deviate from normal (around the age of 29)
in non-index subjects, but one of the last in smokers, in
whom gas transfer and health status deviated first. It is
possible that AATD in the absence of environmental factors is
related initially to mild upper zone emphysema. However
with the added environmental factor of smoking, lower zone
emphysema develops and predominates by the time
a delayed diagnosis21 is made, leading to the observation
that the classical distribution of emphysema in AATD is basal.
There are, however, some limitations to our study, most
notably the design is retrospective and based on deviation
from a normal range rather than a prospective documenta-
tion of trends. A cohort study such as for Swedish subjects
described earlier31 is ideal. Unfortunately the follow-up to
date has been limited mainly to spirometry. Thus, it will beseveral decades before this study yields results which provide
guidance for monitoring non-index subjects appropriately
and cost effectively using FEV1 alone. KCO, health status and
CT have not been assessed in the Swedish cohort until
recently and then in only a small number of subjects, thus the
opportunity to obtain valuable information indicating when
these tests start to deteriorate has probably been lost.
A number of our subjects did not have a CT scan. This
was usually omitted in asymptomatic subjects with normal
lung function or where there were anxieties about the test
such as claustrophobia and radiation exposure, and thus the
data may possibly represent some selection bias. CT
densitometry data was also unavailable for subjects who
had undergone a recent CT scan in their local hospital
which was unsuitable for quantitative analysis due to
acquisition methodology.
Furthermore it is difficult to make assumptions about
the time course in index cases, as most had abnormal test
parameters at the first visit to ADAPT. Thus any attempt to
determine the age at which these became abnormal
requires extrapolation beyond valid data points, rendering
the results uninterpretable. However, clinically it is not
relevant to determine when to test the index subjects, as
by definition, they have already presented with lung
disease and automatically undergo investigation.
There are few young subjects in our cohort especially
index cases. Our youngest index case was 26.4 years old at
diagnosis. The FEV1 was 87.5% predicted whereas the KCO
was 65% predicted, indicating that deterioration of lung
function must have occurred below this age affecting KCO
preferentially, again consistent with the concept of
screening early using non-spirometric tests.
The non-index cases in our cohort are predominantly
family members of index subjects and an influence of
shared genetic susceptibility factors cannot be ruled out.
However, if these are present they are likely, if anything, to
result in the development of lung disease at an earlier age
than non-index subjects with no affiliated index case (such
as those identified by population screening), and recom-
mendations regarding the age at which physiological or
radiological screening should commence would capture the
onset of disease in these patients.
We used two different methods to determine the age at
which test parameters become abnormal, and obtained
reasonable agreement between both. The advantages of
the logistic regression model include the fact that a linear
relationship between age and each test parameter is not
necessarily assumed, and outlying data points have less
impact on the predictions than in the 5 year age-strata
method. Despite the consistency of results obtained using
both methods, the true validity of this type of mathemat-
ical modelling can only be confirmed by a future prospec-
tive study. However the data does provide guidance to
suggest this should include more extensive physiological
testing especially in early adulthood for subjects identified
as having AATD.
Both methods rely on using ‘normal’ values for a healthy
population for each test parameter. For physiology testing,
these values are robust and used frequently.32 However,
little data is available regarding ‘normal’ values for the
SGRQ26 and no normal data for CT densitometry using
the 910 HU threshold is available. We have therefore used
392 J. Holme et al.data from a study reporting a similar but slightly less
sensitive threshold of 912 HU although with a GE Prospeed
CT scanner27 as in our study. This is the best estimate of
normal values that can be applied to the current study.
Nevertheless, these slight uncertainties should be borne in
mind when interpreting the results, and further study of the
use of CT scans and health status scores is warranted.
However, the consistency with predicted deviation from
normal of KCO suggests the data for densitometry is likely
to be a close estimate.
Importantly we have clearly demonstrated that KCO,
health status and UZVI (in never-smokers) deviate from
normal up to 30 years prior to spirometry in non-index
subjects with AATD. Gas transfer deviates from normal in
the teens for smokers and the early 30s for never-smokers.
Based on these data, we recommend that screening for the
development of lung disease should be undertaken in the
20s for non-index never smokers, and the teens for
smokers. KCO is central to this assessment, and in addition
to spirometry, consideration should also be given to utilis-
ing health status and CT measures, although radiation
exposure may restrict the use of the latter. It seems logical
that when KCO is deteriorating, subjects with AATD should
undergo lifestyle modification and possibly start effective
therapies such as augmentation, where available, that has
been shown to influence emphysema progression(20) prior
to the development of FEV1 impairment.
This data challenges the current understanding of COPD,
its’ severity and current treatment guidelines,33,34 as these
are primarily based on spirometry, which becomes impaired
late in the natural history of AATD. It therefore seems
logical to recommend at least lung function testing and
monitoring in subjects known to have AATD from the late
teens and to include gas transfer as part of this routine
follow up to determine whether the data is changing faster
than expected for age. Similar studies of the natural history
of usual COPD in smokers should be considered, as this may
also identify disease at an earlier stage, facilitating the
introduction of appropriate preventative therapy before
airflow obstruction develops.Conflict of interest
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